91910-49-5

Upstream product

• 79250-48-9 methyl 2,5-bis(allyloxy)benzoate 
• 2150-46-1 Methyl 2,5-dihydroxybenzoate 
• 490-79-9 2,5-dihydroxybenzoic acid. 
• 959861-59-7 methyl 2-((R)-2,3-dihydroxypropoxy)-5-((S)-2,3-dihydroxypropoxy)benzoate 
• 95731-73-0 allyl 2,5-bis(allyloxy)benzoate 

Downstream Products

• 932380-53-5 2,5-bis(allyloxy)-N-(benzyloxy)benzamide 
• 959861-61-1 5-((R)-2,3-dihydroxypropoxy)-2-((S)-2,3-dihydroxypropoxy)benzoic acid 

Relevant academic research and scientific papers

GLYCOMIMETICS FOR USE FOR THE TREATMENT OF VASCULAR CALCIFICATION AND/OR ENDOTHELIAL DYSFUNCTION

The present invention relates to the use of glycomimetic compounds for the treatment of vascular calcification and/or endothelial dysfunction, particularly the use of small molecule mimetics of heparin/heparan sulfate, such as compounds according to formula (A), (B), (C) or (D), or pharmaceutically acceptable derivatives thereof

Inhibitors of the FEZ-1 metallo-β-lactamase

Metallo-β-lactamases (MBLs) catalyze the hydrolysis of β-lactams including penicillins, cephalosporins and carbapenems. Starting from benzohydroxamic acid (1) structure-activity studies led to the identification of selective inhibitors of the FEZ-1 MBL, e.g., 2,5-substituted benzophenone hydroxamic acid 17 has a Ki of 6.1 ± 0.7 μM against the FEZ-1 MBL but does not significantly inhibit the IMP-1, BcII, CphA or L1 MBLs.

Novel heparin/heparan sulfate mimics as inhibitors of HGF/SF-induced MET activation

The synthesis of simple, non-sugar glycosaminoglycan (GAG) mimics has been achieved and the analogues evaluated for their ability to inhibit the activation of the MET receptor by hepatocyte growth factor/scatter factor (HGF/SF).